Evommune, Inc. (EVMN)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Evommune, Inc. reported revenue of $13.00M, up 85.7% from the prior year. The company ran a net loss, with a net margin of -529.8%. It held $224.95M in total assets against $19.38M in total liabilities.
Key ratios (FY2025)
-623.6%
Operating margin
-529.8%
Net margin
-33.5%
Return on equity
+85.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $13.00M | $7.00M | — |
| Operating Income | -$81.07M | -$70.01M | — |
| Net Income | -$68.87M | -$66.81M | — |
| EPS (Diluted) | $-11.22 | $-45.29 | — |
| Total Assets | $224.95M | $76.06M | — |
| Total Liabilities | $19.38M | $28.52M | — |
| Shareholders' Equity | $205.57M | -$144.24M | -$77.71M |
| Cash & Equivalents | $44.06M | $16.25M | — |
| Operating Cash Flow | -$76.44M | -$58.20M | — |
| Capital Expenditures | $235.0K | $88.0K | — |
| Shares Outstanding | 31.52M | 1.55M | — |